ArticleFrontiers in oncology2025
Machine learning model for predicting epidermal growth factor receptor expression status in breast cancer using ultrasound radiomics.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: The epidermal growth factor receptor (EGFR) is a clinically important target, as its expression in patients with breast cancer influences both overall and disease-free survival. Current methods for assessing EGFR expression status in a patient are invasive. Therefore, in this study, we developed a machine learning-based approach utilizing ultrasound radiomics to non-invasively predict EGFR expression status in patients with breast cancer. Methods: Radiomic features were extracted from grayscale and wavelet-transformed ultrasound images of 321 patients. The dataset was randomly split into training (n = 225) and test (n = 96) sets at a 7:3 ratio with stratified sampling to preserve the EGFR+/- ratio. Key predictors were identified using a multi-step procedure-including reproducibility filtering (ICC > 0.75), univariate F-test filtering (p < 0.05), and L1-regularized selection via LASSO regression. Seven machine-learning models were trained. Model interpretability was assessed using SHAP (Shapley Additive Explanations). In addition to the hold-out evaluation, we performed stratified 10-fold cross-validation to reduce selection bias. Results: The random forest model demonstrated the optimal performance, with an area under the receiver operating characteristic curve of 0.86 in the training set and 0.70 in the test set. It significantly outperformed the other models (P < 0.001). The Shapley additive explanation method was used to interpret the model, revealing that original_ngtdm_Coarseness, original_ngtdm_Strength, and wavelet.LL_glcm_ClusterProminence were the top predictors. These features reflect structural compactness and heterogeneity associated with EGFR overexpression. Conclusions: We present a reliable and interpretable tool for non-invasively assessing EGFR expression status in patients with breast cancer. The most important predictors captured tumor heterogeneity and microstructural uniformity, highlighting the biological relevance of radiomic patterns in EGFR-positive tumors. This model integrates advanced imaging analyses with machine learning, underscoring the potential of radiomics to advance precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.